New Perspectives of HIV/AIDS Therapy Study

Recent Pat Antiinfect Drug Discov. 2014;9(2):112-20. doi: 10.2174/1574891x10666150109115402.

Abstract

HIV/AIDS (acquired immune deficient syndrome), a human infectious disease was once listed as the No. 1 disease killer in US (1993). After the invention of antiviral drug cocktails-high active anti-retroviral therapy (HAART), most HIV-infected patients can survive much longer than with single antiviral drugs or vaccines alone. However, it turns out to be a chronic disease owing to being incapable to eradicate HIV from infectious patients. Furthermore, potential newly outbreak of HIV epidemics caused by widespread drug-resistance or viral mutations is still looming over the globe. In order to counteract these drawbacks and possibilities of HAART, many hurdles must be passed. More creative and revolutionary ideas and worldwide cooperation efforts among academics, drug developers and governmental funding bodies must be encouraged and promoted. In this perspective, many important drawbacks and weaknesses relating to HIV/AIDS therapies are outlined and possible future solutions are highlighted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / therapeutic use
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use
  • Drug Discovery
  • Drug Resistance, Viral
  • HIV Infections / drug therapy*
  • HIV Infections / prevention & control
  • Humans
  • Patents as Topic

Substances

  • AIDS Vaccines
  • Anti-HIV Agents
  • Antiviral Agents